A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy

Completed · Phase 2/Phase 3

Conditions studied: Parkinson's Disease

In brief

The primary objective of this study was to establish the long-term tolerability and safety of istradefylline treatment in subjects with Parkinson's disease treated with levodopa/carbidopa. In addition, treatment response and maintenance of response were assessed.

Key facts

Study ID

NCT00955045

Run by

Kyowa Kirin, Inc.

Starts

2002-08-01

Expected to finish

2003-10-01

Last updated by the study team

2024-04-25

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Eligible subjects were:
• male or female
• at least 30 years of age
• had completed participation in a prior double-blind istradefylline trial
• met United Kingdom's Parkinson's Disease Society (UKPDS) brain bank criteria (Step 1 and Step 2) for Parkinson's disease and the severity of the Parkinson's disease was defined as Stages 2-4 on the Modified Hoehn and Yahr Scale while in the OFF state
• had been treated with levodopa for at least 1 year
• had been on a stable Parkinson's disease regimen within normal therapeutic ranges including levodopa for at least 4 weeks before Baseline
• were currently taking at least 4 doses of levodopa per day (3 doses per day if at least 2 doses contained slow-release formulation)
• had predictable end-of-dose wearing-off

You may not qualify if…

• none

Where it is running

• 48 Centers in the US and 4 in Canada — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.